FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

Holly Springs, North Carolina Wednesday, April 23, 2025, 14:00 Hrs [IST] ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

Regeneron employee works on a pharmaceutical drug. Photo courtesy of Regeneron Pharmaceuticals HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced ...

FujiFilm Diosynth plans to produce Regeneron's biologic medicines over 10 years in its Holly Springs facility, which is scheduled to begin operations this year.